-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80

Benzinga·07/01/2026 14:02:08
Listen to the news
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $60 to $80.